Please use this identifier to cite or link to this item:
|Title:||Targeting γδ T lymphocytes for cancer immunotherapy : from novel mechanistic insight to clinical application|
|Authors:||Gomes, Anita Q.|
Martins, Duarte S.
|Publisher:||American Association for Cancer Research|
|Citation:||Cancer Res; 70(24) December 15, 2010|
|Abstract:||Abundant interferon-γ secretion, potent cytotoxicity, and major histocompatibility complex–independent targeting of a large spectrum of tumors make γδ T cells attractive mediators of cancer immunotherapy. However, a better understanding of the molecular mechanisms involved in tumor cell recognition and γδ T-cell activation is required to improve the limited success of gd T-cell–mediated treatments. Here, we review key advances in basic knowledge made over the past 3 years, and summarize the results of γδ T-cell–based clinical trials concluded to date. We also highlight new research directions on the basis of the modulation of receptors that control the function of γδ T cells.|
|Description:||© 2010 American Association for Cancer Research|
|Appears in Collections:||IMM - Artigos em Revistas Internacionais|
Files in This Item:
|1_BSS_2010.pdf||193,86 kB||Adobe PDF||View/Open Request a copy|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.